| Gene symbol | APOC3 | Synonyms | APOCIII, Apo-C3, ApoC-3 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q23.3 | dbXrefs | |
| Description | apolipoprotein C3 | ||||
| GTO ID | GTC1427 |
| Trial ID | NCT01647308 |
| Disease | Type 2 Diabetes Mellitus |
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | volanesorsen|ISIS 304801|ApoC-III|Approach|IONIS-APOCIIIRx|Waylivra|ISIS-APOCIIIRX |
| Location approved | EU, UK, Brazil, Canada |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus |
| Year | 2012 |
| Country | United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 304801-CS4 |
| Vector information | |||
|
|||
| Cohort1: ISIS-APOCIIIRX | |||||||||||
|
|||||||||||
| Cohort2: Placebo | |||||||||||
|
|||||||||||